Davis M E, Jones C J, Feneck R O, Walesby R K
Department of Anaesthetia, The London Chest Hospital.
J Cardiothorac Anesth. 1988 Apr;2(2):130-9. doi: 10.1016/0888-6296(88)90262-1.
A study was undertaken to assess the use of intravenous nifedipine in controlling hypertension in patients following coronary artery surgery. A combined hemodynamic and metabolic assessment was carried out in 15 patients on data recorded at six sequential time intervals: (1) baseline, (2) control of blood pressure, (3) 30 minutes after control of blood pressure, (4) 1.5 hours after control of blood pressure, (5) 3.5 hours after control of blood pressure, and (6) 30 minutes after discontinuing nifedipine. Coronary sinus and great cardiac vein blood flows were measured by the continuous thermodilution technique using the Baim coronary sinus flow catheter. Intravenous nifedipine was run initially at an average rate of 1.82 microg/kg/min. It took an average time of 12 minutes to lower the blood pressure to less than 130 mmHg systolic. There were highly significant decreases in systolic, mean, and diastolic blood pressures (P < .001), associated with significant decreases in systemic vascular resistance (P < .001) and left ventricular stroke work index (P < .05). There was an increase in cardiac output at 30 and 90 minutes of infusion (P < .05), and the stroke volume was increased 90 minutes after starting nifedipine (P < .05). The increase in heart rate was not significant. There was no significant effect on conduction times as measured by PR and QRS intervals on the ECG. However, the QTc interval was decreased after 3.5 hours (P < .05). There was an increase in right atrial pressure at 90 minutes and again 30 minutes after stopping nifedipine. (P < .05). The pulmonary artery pressure also was increased after stopping the infusion (P < .05). The pulmonary capillary wedge pressure, pulmonary vascular resistance, and right ventricular stroke work index remained unchanged. Coronary sinus and great cardiac vein flows were maintained despite a decrease in perfusion pressure, suggesting that nifedipine is a potent coronary vasodilator. Indeed, coronary vascular resistance was significantly decreased (P < .05). Myocardial oxygen consumption remained unchanged. The lactate extraction indicated that myocardial metabolism remained aerobic regionally and globally. Thus, the results suggest that blood pressure was easy to control and that there were no adverse effects on atrioventricular conduction, cardiac performance, regional and global myocardial oxygen utilization, or lactate extraction.
开展了一项研究,以评估静脉注射硝苯地平在冠状动脉手术后患者控制高血压方面的应用。对15例患者进行了血流动力学和代谢联合评估,数据记录于六个连续时间点:(1)基线,(2)血压控制时,(3)血压控制后30分钟,(4)血压控制后1.5小时,(5)血压控制后3.5小时,以及(6)停用硝苯地平后30分钟。使用拜姆冠状静脉窦血流导管,通过连续热稀释技术测量冠状静脉窦和心大静脉血流。静脉注射硝苯地平最初的平均速率为1.82微克/千克/分钟。将收缩压降至130 mmHg以下平均用时12分钟。收缩压、平均压和舒张压均显著下降(P <.001),同时全身血管阻力(P <.001)和左心室每搏功指数(P <.05)也显著下降。输注30分钟和90分钟时心输出量增加(P <.05),开始使用硝苯地平90分钟后每搏量增加(P <.05)。心率增加不显著。通过心电图上的PR和QRS间期测量,对传导时间无显著影响。然而,3.5小时后QTc间期缩短(P <.05)。停用硝苯地平90分钟时右心房压力升高,停药后30分钟再次升高(P <.05)。停止输注后肺动脉压力也升高(P <.05)。肺毛细血管楔压、肺血管阻力和右心室每搏功指数保持不变。尽管灌注压力降低,但冠状静脉窦和心大静脉血流得以维持,表明硝苯地平是一种强效的冠状动脉血管扩张剂。事实上,冠状动脉血管阻力显著降低(P <.05)。心肌耗氧量保持不变。乳酸摄取表明局部和整体心肌代谢仍为有氧代谢。因此,结果表明血压易于控制,且对房室传导、心脏功能、局部和整体心肌氧利用或乳酸摄取无不良影响。